MTOR and idiopathic pulmonary fibrosis: Rapamycin, for example, has demonstrated therapeutic effects on IPF in both in vivo and ex vivo studies by inhibiting the mTOR pathway, thereby reducing SASP production and inflammation while slowing cellular senescence (Chrienova et al., 2022).